The research involved experiments with pre-implantation mouse embryos, called blastocysts.
Researchers from University of California, San Francisco in the US found that drugs that inhibit the activity of a master regulator of cell growth called mTOR can put these early embryos into a stable and reversible state of suspended animation.
"Normally, blastocysts only last a day or two, max, in the lab. But blastocysts treated with mTOR inhibitors could survive up to four weeks," said Aydan Bulut-Karslioglu, a postdoctoral researcher at UCSF.
The discovery was a surprise to the researchers, who had intended to study how mTOR-inhibiting drugs slow cell growth in blastocysts, not to find a way to put the embryos into hibernation.
"To put it in perspective, mouse pregnancies only last about 20 days, so the 30-day-old 'paused' embryos we were seeing would have been pups approaching weaning already if they'd been allowed to develop normally," said senior author Miguel Ramalho-Santos from UCSF.
The drugs appear to act by reducing gene activity across much of the genome, the team found, with the exception of a handful of so-called "repressor" genes that themselves may act to inhibit gene activity.
The researchers tested a number of different mTOR inhibitors and found that the most effective was a new synthetic drug called Rapa-Link that was recently developed at UCSF by the lab of Kevan Shokat.
The researchers believe that it should be possible to extend the suspended animation for much longer than the 30 days observed in the present study.
Researchers showed that the dormant state they were able to induce in blastocysts by blocking mTOR was almost identical to the natural ability of mice to pause a pregnancy in its early stages.
This temporary stasis, called diapause, occurs in species across the animal kingdom, and in mammals from mice to wallabies, it typically allows mothers to delay pregnancy when food is scarce or they are otherwise stressed.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
